newsfilter
← Latest News
Business Wire·

Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%

PAYS
  • Paysign, Inc. reported Q3 2026 revenues of $30.80 million, a 42.6% increase from Q3 2025.
  • Pharma industry revenue more than doubled to $16.62 million, up 109.8% year-over-year, driven by 62 net new patient affordability programs.
  • Plasma revenue increased 7.5% to $13.83 million despite a 33-center reduction in the net center count to 562 centers.
  • Gross profit margin expanded to 64.7% in Q3 2026 from 56.3% in Q3 2025, while operating margin rose to 23.8% from 7.3%.
  • GAAP net income for the quarter reached $6.74 million, or $0.11 per diluted share, compared to $2.22 million in the prior year period.
  • Adjusted EBITDA increased 118.0% to $10.98 million in Q3 2026 from $5.04 million in Q3 2025.
  • The company confirmed full-year 2026 revenue guidance of $114.0 million to $117.0 million.
  • Paysign raised full-year 2026 guidance for gross profit margin, net income, GAAP diluted EPS, and adjusted EBITDA.
  • Subsequent to the quarter, a plasma customer notified Paysign of transitioning payment processing for 113 centers to another provider by year-end, impacting Q4 estimates.
  • The company exited the quarter with $34.54 million in unrestricted cash, $201.79 million in restricted cash, and zero bank debt.
  • Operating expenses increased 19.2% to $12.60 million, with selling, general, and administrative expenses rising 22.8% to $10.29 million.
  • The company expects to exit 2026 with 190-195 active patient affordability programs and 445-450 plasma centers.